Tulasee Bio-Eth. (524514)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me start with the simple truth: I cannot value a business that has no sales. Tulasee Bio-Eth's latest quarter shows revenue of ₹0 crore and net profit of ₹0 crore. With a Piotroski F-Score of 2/9, the fundamentals are weak. Graham taught me to buy with a margin of safety, not hope. At ₹17.73, the market cap is ₹11 crore, but book value per share is only ₹1.35 – so I am paying 13.13 times book for a commodity chemical company that is destroying value. ROE is -24.60% and ROCE is -1.61%; this is a capital destroyer, not a compounder. There is no dividend, no demonstrated growth, and profit growth has collapsed by 100%. The price has fallen from ₹71.21 to ₹17.73, which might look like opportunity, but a falling stock is not the same as an undervalued business. Mr. Market is depressed, and maybe he will offer lower prices. But I need the business to survive and eventually earn. With book value of only ₹1.35 per share, the current price already capitalizes a huge recovery. If sales don't restart, equity can keep eroding. The lack of promoter holding data and a debt/equity figure of N/A mean I cannot assess whether insiders share my pain or whether hidden liabilities exist. This is a speculative instrument, not an investment. If forced to file it, I would call it a turnaround candidate – but only in the sense that it needs a complete operational rebirth. I watch from the sidelines until actual revenue returns and the balance sheet becomes clean.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer